The prevalent stigmatisation of Down Syndrome in Singapore can fuel an IVF profiteering machine.
Key points at a glance:
- Singapore is reviewing whether embryo genetic screening should become routine in public IVF clinics.
- In a competitive society, the test could be viewed as essential insurance against chromosomal conditions like Down syndrome.
- However, early biopsies cannot guarantee accuracy because embryonic cells can self-correct during development.
- Overseas lawsuits highlight the risk of wrongly discarding viable embryos based on uncertain reports.
- Couples need transparent medical guidance rather than fear-based marketing to make informed choices, and Singapore should reveal the PGT-A pilot’s methodology and data.
As Singapore weighs whether embryo genetic screening with PGT-A belongs in routine IVF, the latest data from a pilot trial appear encouraging… but is far from a blank cheque.
For couples already stretched by the emotional and financial strain of IVF, a new genetic screening test can sound irresistible to older women at higher risk of having a baby with Down syndrome. That is the promise attached to preimplantation genetic testing for aneuploidy, better known as PGT-A.
But PGT-A is not a crystal ball. It samples a few cells from an early embryo and estimates whether the embryo has the right number of chromosomes. The result may influence which embryo is transferred first, which is frozen, and which may never be given a chance.
Singapore’s IVF landscape is now at a pivotal moment. PGT-A is not yet a routine mainstream clinical service. It is being evaluated at public assisted-reproduction centres, while policymakers consider what the evidence really shows and what safeguards patients need.
Read the Fine Print
In a written parliamentary reply dated 4 August 2026, the Ministry of Health (MOH) reported that 303 women had undergone PGT-A in a public-sector pilot trial as of 31 January 2026. The procedures were associated with 119 pregnancies and 92 live births. MOH said the pregnancy rate was higher with PGT-A and that it is reviewing the pilot scheme.
The headline figures, however, come from a carefully selected group. The subsidised pilot trial is for women aged 35 or older who have experienced at least two recurrent implantation failures, at least two pregnancy losses, or at least two embryos or foetuses with chromosomal abnormalities. That is not the same population as every older woman pursuing IVF.
The distinction matters. A promising result in patients with specific medical histories cannot automatically be treated as proof that every IVF patient should buy the test. The trial data is still preliminary, and the government’s review is the next development to watch.
The parliamentary update also raises a practical question: if PGT-A is eventually expanded, will couples receive a clear explanation of what the test can detect, what it cannot detect and how uncertain results should be handled?
When Fear Becomes a Business Opportunity
The pressure surrounding PGT-A is not only medical. In Singapore and elsewhere in Asia, many people delay parenthood while facing rising costs, falling fertility and intense expectations about what a successful family should look like. Down syndrome can become shorthand for a frightening future, even though a diagnosis does not describe a person’s entire life or a family’s capacity to love and thrive.
That anxiety can make an expensive test feel less like a choice than a duty. Clinics may present PGT-A as a way to “reduce risk” or protect a future child. Patients may hear a stronger message: declining the procedure means being irresponsible and accepting avoidable danger.
Reports on the IVF industry’s exploitation of Down syndrome anxiety have highlighted why counselling must separate genuine medical information from fear-based salesmanship. Singapore’s fertility-health conversation should therefore include disability awareness, not just laboratory statistics.
The country’s own public-education challenge is broader than embryo selection, because families must feel supported even if a child does not fit an imagined template of perfection. ‘Tiger parenting’ may be a stereotype, but it speaks to the idea of a future child as a high-stakes performance project. But a child is certainly not a score, a chromosome report or an investment whose value can be calculated before birth.
A Genetic Test Is Not a Verdict
PGT-A involves a biopsy of the embryo’s outer layer, from cells that will contribute mainly to the placenta, while the inner cell mass develops into the foetus. That sample may therefore not perfectly represent the embryo as a whole.
This is where mosaicism enters the story. A mosaic embryo contains a mixture of cells with different chromosome patterns (normal and abnormal). A report that labels an embryo “abnormal” or “mosaic” can sound final, but biology is more complicated than a red or green light.
Research on embryonic self-correction has suggested that some abnormal cells may be eliminated or outcompeted as development continues. Healthy births have been reported after the transfer of embryos once classified as mosaic or abnormal. That does not mean every mosaic or abnormal embryo is viable; it means that uncertainty should not be disguised as certainty.
The test also has a narrower scope than many patients assume. PGT-A looks primarily for large-scale chromosome-number abnormalities. It does not predict intelligence, personality, autism, mental health, happiness, or the quality of a child’s future. A known single-gene condition, such as thalassaemia, calls for a different test—PGT-M—not PGT-A.
The result is a probability statement based on a small sample, not a guarantee of a healthy baby. Any clinic presenting it as an all-purpose quality-control system is overselling what the technology can do.
The Global Evidence Isn’t So Tidy
Large clinical studies outside Singapore have not produced a simple “PGT-A works for everyone” answer. The multinational STAR trial found no significant overall improvement in ongoing pregnancy rates across age groups, while a major Chinese study found no better cumulative live-birth outcome than conventional IVF. A very large database analysis also found that routine PGT-A could be associated with lower cumulative live-birth rates in some groups, particularly younger women.
Those findings do not make PGT-A useless, but they do make universal claims difficult to defend. The right question is not whether PGT-A sounds high-tech, but whether it improves the outcome for a particular patient after the patient understands the trade-offs.
There are also alternatives at later stages of pregnancy. Non-invasive prenatal testing, or NIPT, uses the mother’s blood sample to screen for Down syndrome. Advanced ultrasound can also detect Down syndrome. The existence of alternative options underscores the need to discuss the least invasive and most appropriate route for each patient, rather than treating genetic testing with PGT-A as an automatic upgrade.
Legal Consequences
The unreliability of PGT-A and its risks of misdiagnosis are now reaching the courts. In Australia, Monash IVF agreed in 2024 to an AUD$56 million settlement with more than 700 former patients who alleged that potentially viable embryos had been discarded after inaccurate genetic screening.
Similar class-action lawsuits in the USA alleging that providers of PGT-A testing have likewise misled patients about PGT-A’s accuracy, have also been filed.
What if indeed, thousands of potentially healthy babies have been discarded through a test more about marketing than medicine?
What Singapore Should Do Next
Singapore should publish the PGT-A pilot’s full methods and comparison data—not just headline figures—so its outcomes can be independently assessed.
Before paying, every patient should receive clear counselling on biopsy risks, mosaicism, false reassurance, viable embryos being excluded, and the limits of a screening test that is not a diagnosis. Counselling must also address Down syndrome honestly: real risks, available support, and the lived reality of people with Down syndrome—not fear alone.
A targeted pilot must not become a routine consumer service where “perfect embryos” are treated as a prerequisite for parenthood.
This is not science versus emotion. It is a test of whether science is communicated truthfully when patients are most vulnerable. Until prospective parents can clearly answer what PGT-A can reveal, what it can miss, and which decisions it may alter, caution is not anti-science—it is informed consent.
Dr Alexis Heng Boon Chin is a Singaporean biomedical scientist and bioethics researcher. His work examines the ethical, legal and social implications of IVF, embryo genetic testing, reproductive genetics and emerging fertility technologies.
